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by simply using affordable interventions, most of which cost 
no more than US $5 per person, on an average.[1,2]
Several viruses and bacteria belong to the dreaded group of 
infectious diseases, some of which, although preventable, 
are transmitted vertically and horizontally.[4,5] In pregnancy, 
they either cross the placenta to cause congenital infections 
in the fetus, abortion, intrauterine death, preterm labor or 
infect the baby perinatally as it passes through the birth 
canal of the mother or in postnatal life, through breast milk, 
as in HIV.[5] Rubella virus is among the microorganisms 
Introduction
The burden of infectious diseases is great. Infectious 
diseases inflicted a new magnitude of suffering after the 
world entered the last millennium. They are among the 
biggest disablers and killers of the young.[1] According the 
World Health Organization,(WHO), as diseases continue 
to catch the world off guard, near misses are on the increase 
and the future is uncertain. Medicines are losing their 
effectiveness and the world is becoming a smaller place for 
microbes.[1] Fortunately, however, most of these diseases 
are affordable to prevent, avoidable at a low cost, and 
controllable in any country.[1-4] Among the cases of death, 
at least half, and in some cases nearly all, could be avoided 
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that can be transmitted from mother to child (MTCT).[2-4] 
It is a non-sexually transmittable viral infection with mild 
febrile symptoms and a rash in adults and children,[2] and 
occasional outbreaks.[6] In pregnancy, it may lead to serious 
congenital anomalies, still births and increased perinatal 
mortality.[6-10] As the rubella virus was first isolated in 1962 
by Parkman, Beuscher, and Arenstein, and independently 
by Weller and Neva[11] as co-discoverers, a syndrome of 
severe bilateral sensorineural deafness, cataracts, mental 
retardation, microcephaly, and congenital heart defects 
among others, known as the congenital rubella syndrome 
(CRS), was recognized over 50 years ago.[7-12]
In the United States of America (USA), approximately 
20,000 cases of CRS were reported in the mid-1960s, 
during an outbreak, from 1964 to 1965.[11] The associated 
economic cost for medical attention was astronomical, 
costing at least US $220,000 per case.[11,12] To eliminate 
this ugly scenario, significant efforts were made to prevent 
further outbreaks by massive immunization campaigns 
across the USA, Latin America, and Europe, while the year 
2010 was targeted for the elimination of rubella infection 
and new cases of CRS across these regions.[13-19] Despite the 
potentially devastating effects of CRS, many developing 
countries are yet to embrace prevention and immunization 
programs against rubella, and where such programs exist 
the immunization rates are sub-optimal.[2,4,11] Consequently, 
rubella infections in pregnancy still occur with CRS often 
diagnosed in postnatal life.[4,9,14]
Inadequate response, poor investment in health development, 
and many developing countries not using the World 
Health Organization (WHO) recommended policies have 
encouraged the spread of the infection. Sporadic outbreaks 
of rubella infection, with its associated significant harm, 
makes full immunization in childhood and in women of 
child-bearing age, imperative.[1,3,6] As the development of 
new drugs and vaccines continue and the need for research 
intensifies, the products are often out of reach of the majority 
of persons in poor or developing countries.[1] In an era of 
scarce resources, the need for the rational use of resources has 
become imperative and establishment and implementation of 
new prevention programs must be evidence-based. In other 
words, the task of furthering health and development begins 
by identifying achievable and cost-effective interventions 
that provide substantial benefits to communities. In spite 
of the high perinatal mortality rate in Nigeria, screening 
for and vaccination of women and children against rubella 
is neither part of antenatal care nor among the diseases 
recommended for vaccination, in the National Program on 
Immunization (NPI).[4,13] Rubella infection and CRS are not 
reportable diseases in Nigeria. Fortunately, however, rubella 
is a vaccine-preventable disease.
In Nigeria, the national prevalence of rubella infection, 
whether in- or out-of pregnancy, and CRS is unknown. 
In the last two decades, there have been scanty reports of 
rubella infection from few centers across Nigeria,[13,20-22] 
but information from the Nigerian Niger Delta is scarce. 
Also, no assessment of combined IgG and IgM seromarkers 
for previous and current rubella infections has been 
reported in a single study in the country. The feasibility 
of establishing a screening and vaccination program has 
not been addressed. In a low-income country like Nigeria, 
where rationalization of available scare resources is 
needed, obtaining a government political will for positive 
interventions requires evidence-based advocacy. The need 
to provide this information through the determination of 
sero-susceptibility of rubella infection in pregnancy and the 
feasibility of establishing an organized prevention program 
in Nigeria, including vaccination against rubella, is the 
justification for this study.
Materials and Methods
Three hundred women were counseled and volunteers 
had their biodata recorded in a standard questionnaire and 
then they were screened for rubella IgG and IgM antibodies 
using the ELISA-based quantitative assay, at the Virology 
Laboratory of the Hospital. Of the cohort, 270 women 
volunteered and were recruited for the study. Ten milliliters 
of blood was collected by an aseptic technique from the 
antecubital veins of the volunteers into bottles containing 
ethylene diamine tetra-acetic acid (EDTA) anti-coagulant. 
The sera obtained after centrifugation were quantitatively 
analyzed for IgG antibodies using the RUB IgG Test kit (Dia 
Pro. Diagnostic Bioprobes SrI, Columella Milano, Italy), 
according to the manufacturer’s instructions.[23] Samples 
with IgG antibody ≥10.0 IU/ml were considered positive and 
further subjected to IgM antibody analysis, using the RUB 
IgM Test kit, according to the manufacturer’s instructions.[23] 
The IgG seropositive cases were regarded as exposed (previous 
or current), while the IgM seropositive cases were regarded 
as acute or active infection.
This study had the Hospital Ethical Committee’s approval.
The laboratory protocol
The antibody assay
Antibodies of immunoglobulins G (IgG) and M (IgM) 
were assayed by the Plate ELISA Method. Quantitative 
IgG results were expressed in international units (IU), 
with calibration performed against reference standards of 
10, 20, 50, 100, and 250 IU/mL for IgG, according to the 
manufacturer’s instruction.[23] The confirmation of IgM was 
performed by an indirect ELISA assay and expressed as a 
qualitative result.
Specifically, with the aid of a Stat Fax Auto Washer and Stat 
Fax Microplate Reader 2600 ELISA machine (Awareness 
Technology USA) the specimens were analyzed for Rubella 
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IgG and IgM antibodies, using RUB IgG and RUB IgM 
test kits by the quantitative and qualitative methods, 
respectively.[23]
Discrimination between IgG seronegative and seropositive 
samples
The concentration of 10 IU/ml was used to discriminate 
between negative and positive samples after standardization 
of the equipment in accordance with the Manufacturer’s 
Instructions Manual for IgG.[23] Samples with IgG antibody 
concentration ≥10 IU/ml were regarded as seropositive or 
exposed cases (previous or current), while samples <10 IU/
ml were considered seronegative and unexposed.
Confirmation tests for IgM antibodies
The IgG seropositive samples were further analyzed for IgM 
using RUB IgM according to the manufacturer’s instructions 
for IgM.[23]
Principles of the IgM assay
The microplates were coated with a monoclonal anti-human 
IgM (hIgM) antibody that in the first incubation specifically 
‘captured’ this class of antibodies. After washing out all the 
other components of the sample, in the second incubation, 
bound anti-Rub IgM were detected by the addition of 
purified and inactivated Rub antigens, complexed with a 
specific monoclonal antibody, and labeled with peroxidases 
(HRP). The enzyme captured on the solid phase, acting 
on the substrate/chromogen mixture, generated an optical 
signal that was proportional to the amount of IgM antibodies 
present in the sample and could be detected by an ELISA 
reader.[23]
Criteria for the validity of the assay[23]
The assay was considered valid:
1. When the OD450nm of the A1 blank well was <0.100
2. After blanking on A1, the OD450 nm mean value of 
the Negative Control (NC) was <0.200
3. The OD450 nm mean value of the positive control (PC) 
was >1.00.
The test assay meant that all these criteria with our NC 
were 0.068.
The cut off value was NC + 0.250 = 0.318
Calculation of results
Samples with an OD450 nm value lower than the cut-off 
were classified as negative for Rub IgM. Samples with an 
OD450 nm value within the cut-off +20% were considered 
to be in the gray zone. Samples with an OD450 nm value 
higher than the upper limit of the gray zone were classified 
as positive.[23]
Sensitivity and specificity of the IgM assay
The Sensitivity and Specificity of the IgM assay using RUB 
IgM are both known to be >98% when compared with the 
FDA (Food and Drug Administration, USA) approved kits 
present in the market.[23] The presence of a positive IgM 
antibody test is an evidence of current or active infection.
Data analysis
The data were expressed as percentages and differences 
between groups were assessed by the Chi-square (c2) test 
using GraphPad Instat3, version 3.06, 32 bit for windows, 
2003 software (GraphPad Software Inc. San Diego, 
USA). A P value of <0.05 was considered statistically 
significant.
Results
The mean age and parity of the study population 
[Table 1] were 30.3 ± 4.8 (range 16-45) years, 95% CI 
29.727-30.873 and 1.5 ± 1.4; 95% CI 1.317-1.661 (range 
0-7), respectively.










Total  270 100.0
Marriage status
Single  5 1.8
Married 265 98.2
Total 270 100.0
Table 2: Frequency of sero-positive and negative tests 


























143 14 2 127 9.7
IgG negative 
test, but with 
samples titers 
8.5 to 9.9 IU/ml 
10 0 1 9 0.0
Total 153 14 3 136 9.2
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The majority, 57.0 and 91.3%, were seronegative for IgG 
and IgM antibodies, respectively. The borderline results 
could not be confirmed further [Table 2].
Nulliparous women were 84 (31.1%), while women with 
parity ≥1 were 186 (68.9%). The relationship of parity with 
IgG serostatus is as shown Figure 1.
One hundred and eleven (51.4%) women with positive IgG 
seromarkers were less than 35 years of age, while 32 (59.2%) 
were above 35 years of age. There was no statistically 
significant difference between the age groups; P = 0.36, 
RR 1.19; 95%CI 0.84-1.69. Similarly, of the 84 nullipara, 
63 (75%) were seropositive, while 44.1% of the women 
who were para 1 or more were IgG seropositive. Nulliparous 
women were more likely than parous women to have rubella 
infection, P < 0.000, RR 0.4897; 95%CI 0.3379-0.7097 
[Figure 1]. The IgG serostatus of the study population is as 
shown in Table 2 and Figure 2.
The IgM seropositivity was 9.7% in the IgG seropositive 
samples. When combined with the IgG seronegative 
samples near the discriminatory zone, the IgM prevalence 
dropped to 9.2% [Table 2, Figures 2 and 3]. The samples 
whose titers were near the discriminatory zone were IgM 
seronegative.
Discussion
This study has shown that rubella is quite common and 
active among the pregnant population. None of the women 
was symptomatic. This was probably due to the mild nature 
of the infection, which could easily be confused with the 
malarial fever endemic in Nigeria. Asymptomatic carriers of 
20 to 50% have been reported in other studies.[2,6,7]
The mean age of 30.3 ± 4.8 years is comparable with 
28.1 ± 1.7 years reported by Pena et al.[20] from the middle 
belt of Nigeria. A majority of 80% of the women was younger 
than 35 years[Table 1]. The mean parity was 1.5 ± 1.4, while 
over 31% of the study population was nulliparous. Although 
women less than 35 years, or more, did not significantly 
differ in the risk of infection, P = 0.36, RR 1.19, nulliparity 
was associated with rubella infection, P < 0.000, RR 0.4897 
[Figure 1]. A woman’s risk of acquiring the infection should 
expectedly increase with increasing age and parity, due 
to the longer duration of interaction with an infectious 
environment. The non-significant difference associated with 
the age below ≥35 years in this study, could suggest that 
most infections were probably acquired before that age. In a 
study to determine the prevalence of rubella antibodies and 
age of exposure to rubella among 323 Yemeni schoolgirls of 
age 11-21 years, Sallam et al.[24] reported 91.64% rubella IgG 
antibody seropositivity, indicating that a majority of the girls 
were naturally immune by age 11-21 years.
The association of nulliparity with the risk of rubella 
infection might be a chance finding as pregnancy is 
not known to be protective against rubella infection. 
Alternatively, the intentional delay in marriage and child 
bearing due to a quest for higher education could have led to 
prolonged exposure to the virus from various environments, 
as students are generally more mobile than married women. 
In this study, 1.8% of the women were single ladies, more 
than 31% nulliparous, and approximately 20% had children 
Figure 1: 100% stacked cylinder relationship of parity and  
IgG serostatus
Figure 2: IgG seropositive and seronegative sub-populations
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at relatively older ages (35-45years). Single motherhood, no 
doubt, can exert some physical, psychological, and financial 
strain on the mothers, especially in this environment where 
there is no social security. The social status of women is 
low, poverty is high, and single parenthood is viewed with 
derision.[25,26]
The reported prevalence of rubella IgG of 53% in this study 
is much lower than 85-90% in European women[11] and 
91.64% in Yemini adolescents, but about 54-76% has been 
reported from other parts of Nigeria.[13,20-22]
The IgM seropositivity was 9.7% in IgG seropositive 
samples and 9.2% when combined with samples near the 
discriminatory zone [Table 2, Figures 2 and 3], but the later 
samples were also IgM negative, thus confirming the high 
sensitivity and specificity of the test kits.[23]
The IgM prevalence rate of 9.7% is about three-fold, with 3.9% 
reported for the middle belt of Nigeria,[21] and is comparable to 
the 11.4% reported for Cord blood in children of Costa Rica.[27] 
Sporadic outbreaks of rubella, every four to seven years, have 
been reported in America, various European countries, Japan, 
Costa Rica, Panama, and Brazil.[11,16,17,19,27-30] Outbreaks, which 
may go unrecognized due to the mild nature of the infection, 
could account for variation in prevalence of rubella IgG and 
IgM antibodies in various populations.
None of the women, including the infected patients, had ever 
had prophylactic vaccination. Antenatal health-talks in Nigeria 
routinely do not incorporate information on Rubella infection. 
Vaccination against rubella is also not part of the Nigerian 
national or local immunization programs.[4,21] Preconception 
counseling of women of reproductive age about rubella is also 
not routine in Nigeria. Concerted efforts to combat the spread 
of HIV/AIDS through seminars, workshops, outreaches, and 
electronic and print media is yielding dividends resulting 
in the decline of the national prevalence of HIV, but the 
campaigns do not include rubella.[26] General knowledge about 
rubella may thus be poor. In developed countries of North 
and Latin America and Europe, the goal taken in 2003, to 
eliminate rubella and CRS by 2010, is being pursued with 
vigor, after having met the goal that eliminated polio by 1991, 
and eradicated measles in 2000, with the introduction of the 
combined MMR (Measles, Mumps, Rubella) vaccination 
in pediatric vaccination schedules.[11] In an attempt to 
eliminate rubella infection and prevent new cases of CRS, 
Brazil in September 2008, targeted adolescents and adults and 
vaccinated 70 million men and women across the country; one 
of the greatest rubella vaccination campaign in history.[11,17] 
Unfortunately many developing countries including Nigeria 
is yet to learn from these experiences.
It is desirous to vaccinate the seronegative women and all 
the infants in this study in the puerperium. This initiative 
could not be realized, as Rubella vaccine was not available. 
All attempts to secure the vaccine failed. Generally, vaccine 
procurement and distribution is the responsibility of the 
Federal Government of Nigeria, occasionally supported by 
international partners. The lack of vaccine is a reflection 
of the poor attention paid to rubella infection. Poverty has 
been noted to be a major constraint in poor or developing 
countries in getting the products needed for prevention and 
control of infectious diseases,[1] and Nigeria is still entangled 
in this dilemma. The serious congenital anomalies of 
CRS[7,14,16,17] are preventable, and all efforts by stakeholders 
to achieve this goal would be noble.
Rubella vaccination was earlier believed to be contraindicated 
during pregnancy and for women intending to get pregnant 
within three months of vaccination, because of theoretic 
concerns about fetal damage with the live-attenuated 
vaccine. In spite of this, no real risk of CRS after rubella 
vaccination during pregnancy has been reported in 
scientific literature.[6,11,33-35] The overall theoretical risk of 
severe malformations attributed to the RA 27/3 vaccine 
against rubella varies from 0 to 1.6%.[11,17] Thus, a window 
of opportunity exists during antenatal care, to counsel 
women for vaccination, at best in the immediate partum 
period, if risk of vaccine-associated fetal malformation is a 
concern. The period of vaccination of children in the NPI is 
another opportunity for women’s vaccination, as women are 
mostly involved in getting their children to immunization 
centers. The routine vaccination of girls in early teens was 
a major contribution to the prevention of rubella infection 
in pregnancy, in developed countries.[17,30-35] Extension of 
immunization to non-pregnant women of reproductive age 
and men is a key element in maintaining the current high 
immunization rates that ensured high herd immunity. [17] 
Missed opportunities for vaccination are responsible for 
new cases of rubella and CRS.[11]
We are aware of the possible cross-reaction of rheumatoid 
IgG complexes mimicking IgM antibody. Due to logistic 
constraints, we were unable to exclude other sources of 
potential IgM cross-reacting antibodies, such as CMV, 
EBV, Toxoplasma, and Parvovirus infections. However, 
the presence of rubella-specific IgM or a significant rise 
in rubella-specific IgG is indicative of recent infection.[7] 
Unfortunately, there are no medications for mothers with 
active infections. Even so, routine antenatal testing for 
rubella antibody is a good practice irrespective of a woman’s 
seronegative status in a previous pregnancy.[7]
Where a woman was immunized to rubella and she 
had contact with rubella in early pregnancy, the CDC 
recommended that the patient and her physician make 
the final decision regarding continuing the pregnancy.[6] 
Termination of pregnancy could be offered, if infection 
was confirmed. Except for proven medical reasons of life-
incompatible malformations, induced abortion is illegal 
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and litigious in Nigeria. For religious and cultural reasons, 
discussing induced abortion can tear members of the same 
family apart in Nigeria.[36]
Conclusions
We have not only provided evidence of high previous and 
current rubella infections in pregnancy, but this study has 
also highlighted the difficulties associated with initiating 
organized routine screening and vaccination programs in 
antenatal clinic settings in this country, due to the scarcity 
of rubella screening kits, vaccine, and immunization 
schedules. These are serious critical issues that should be 
addressed before the establishment of such programs. The 
incorporation of the triple MMR vaccine into the NPI and 
integration of rubella prevention program into the antenatal 
care services will be a cost-effective intervention, rather 
than to wait and treat the sequelae of CRS.
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